GSK
GSK plc
$51.25
+1.20%
$103.3B
No data for this timeframe.
Vol
Market Cap$103.3B
Cap SizeLarge Cap
Inst. Holders11 funds
Inst. Value$7.3B
Inst. Activity0 buys / 3 sells
Reddit Sentiment50° Neutral
SEC Reports4
Recent Activity
Jun 9, 2026
SEC
The District Court for the Eastern District of Pennsylvania granted GSK's motion to dismiss a securities fraud class act
COURT-RULING — Impact 6/10
Apr 13, 2026
SEC
GSK plc repurchased 325,000 ordinary shares on April 10, 2026, as part of its ongoing buyback program, at a volume-weigh
6-K — Impact 3/10
Mar 30, 2026
SEC
GSK plc announced that China's National Medical Products Administration (NMPA) has approved Exdensur (depemokimab) for t
6-K — Impact 7/10
Inst.
RENAISSANCE TECHNOLOGIES LLC — TRIM
1,035,572 shares ($50.8M)
Inst.
TWO SIGMA INVESTMENTS, LP — TRIM
36,300 shares ($1.8M)
Jun 3, 2026
clinical_trial_readout
T-90d Trial Readout: Dostarlimab (Phase 2)
Trial: A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants
Mar 27, 2026
Event
ZEJULA
Supplemental Approval — Labeling — NIRAPARIB — TABLET — ORAL
Mar 4, 2026
Event
Roofers Local No. 149 Pension Fund, on behalf of itself and all others similarly situated v. GSK PLC, et al.
Court ruling from District Court, E.D. Pennsylvania. Docket: 2:25-cv-00618
Price Targets
Historical data — last covering-analyst action Jan 2026. No current recommendation available.
$56.63 (Jan 2026)
Current $51.25
Low $47.00
Median $54.00
High $70.00
7 analysts
$47.00
$70.00
Analyst Ratings
6Strong Buy
8Buy
14Hold
4Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jan 6, 2026 | Barclays | DOWNGRADE | Equal-Weight → Underweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $1.25 ▼ -3.0% | $1.24 — $1.26 | 1% YoY | 2 |
| Next Q | $1.44 ▼ -2.2% | $1.40 — $1.48 | -1% YoY | 2 |
| Current FY | $4.84 | $4.74 — $4.97 | 3% YoY | 3 |
| Next FY | $5.23 ▲ +0.5% | $5.12 — $5.45 | 8% YoY | 3 |
Latest Reports
BULLISH
COURT-RULING
6/10
The District Court for the Eastern District of Pennsylvania granted GSK's motion to dismiss a securities fraud class act
Jun 9, 2026
NEUTRAL
6-K
3/10
GSK plc repurchased 325,000 ordinary shares on April 10, 2026, as part of its ongoing buyback program, at a volume-weigh
Apr 13, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| DODGE & COX | $3.4B | — |
| FMR LLC | $3.3B | — |
| MORGAN STANLEY | $285.8M | TRIM |
| BANK OF AMERICA CORP | $184.1M | ADD |
| WELLS FARGO & COMPANY/MN | $124.4M | ADD |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
11 institutional holders with $7.3B total value (149,697,229 shares) as of 2025-Q4. Top holders: DODGE, FMR, MORGAN. Net selling activity: 3 institutions trimmed/exited vs 0 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | DODGE & COX | 68,517,969 | $3.4B | 45.8% | — |
| 2 | FMR LLC | 67,469,409 | $3.3B | 45.1% | — |
| 3 | MORGAN STANLEY | 5,828,663 | $285.8M | 3.9% | TRIM -28.0% |
| 4 | BANK OF AMERICA CORP /DE/ | 3,753,102 | $184.1M | 2.5% | ADD +99.8% |
| 5 | WELLS FARGO & COMPANY/MN | 2,535,850 | $124.4M | 1.7% | ADD +96.7% |
| 6 | RENAISSANCE TECHNOLOGIES LLC | 1,035,572 | $50.8M | 0.7% | TRIM -47.9% |
| 7 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 289,888 | $14.2M | 0.2% | ADD +35.1% |
| 8 | Hillman Capital Management, Inc. | 114,336 | $5.6M | 0.1% | TRIM -28.6% |
| 9 | Tweedy, Browne Co LLC | 82,243 | $4.0M | 0.1% | — |
| 10 | TWO SIGMA INVESTMENTS, LP | 36,300 | $1.8M | 0.0% | TRIM -59.4% |
| 11 | CAUSEWAY CAPITAL MANAGEMENT LLC | 33,897 | $1.7M | 0.0% | NEAR_EXIT -97.1% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 1,987,953 | 1,035,572 | -47.9% | $50.8M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 89,500 | 36,300 | -59.4% | $1.8M | 2025-Q4 |
| CAUSEWAY CAPITAL MANAGEMENT LLC | NEAR_EXIT | 1,177,001 | 33,897 | -97.1% | $1.7M | 2025-Q4 |
| NORGES BANK | EXIT | 55,000 | 0 | -100.0% | $0.00 | 2025-Q3 |
| UBS Group AG | TRIM | 8,052,055 | 5,278,287 | -34.4% | $202.7M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | ADD | 2,536,715 | 5,068,687 | +99.8% | $194.6M | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | ADD | 1,432,720 | 2,818,481 | +96.7% | $108.2M | 2025-Q2 |
| NORGES BANK | NEW | — | 55,000 | — | $2.1M | 2025-Q2 |
| CITADEL ADVISORS LLC | ADD | 1,857,714 | 2,921,574 | +57.3% | $113.2M | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 2,755,193 | 1,982,153 | -28.1% | $76.8M | 2025-Q1 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 126,647 | 171,145 | +35.1% | $6.6M | 2025-Q1 |
| Hillman Capital Management, Inc. | TRIM | 231,151 | 165,143 | -28.6% | $6.4M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | NEAR_EXIT | 574,754 | 89,500 | -84.4% | $3.5M | 2025-Q1 |
| UBS Group AG | DOUBLED | 938,841 | 6,900,908 | +635.0% | $233.4M | 2024-Q4 |
| MORGAN STANLEY | TRIM | 7,953,833 | 5,726,994 | -28.0% | $193.7M | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 121,603 | — | $5.0M | 2024-Q3 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
4 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 4.8/10.
BULLISH
COURT-RULING
6/10
The District Court for the Eastern District of Pennsylvania granted GSK's motion to dismiss a securi
Jun 9, 2026
NEUTRAL
6-K
3/10
GSK plc repurchased 325,000 ordinary shares on April 10, 2026, as part of its ongoing buyback progra
Apr 13, 2026
BULLISH
6-K
7/10
GSK plc announced that China's National Medical Products Administration (NMPA) has approved Exdensur
Mar 30, 2026
NEUTRAL
6-K
3/10
GSK plc announced the purchase of 345,000 of its ordinary shares on 25 March 2026 at a volume-weight
Mar 26, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Jan 2026): 44% buy across 32 analysts — 6 strong buy, 8 buy, 14 hold, 4 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Jan 2026. No current recommendation available.
$56.63 mean target (Jan 2026)
$47.00 Low
$70.00 High
| Metric | Value |
|---|---|
| Current Price | $51.25 |
| Target Low | $47.00 |
| Target Mean | $56.63 |
| Target Median | $54.00 |
| Target High | $70.00 |
| # Analysts | 7 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$1.25 | $1.24 | $1.26 | 0.6% | -3.0% | 0↑ 2↓ | $8.2B | 3.0% | 2 |
| Next Q 2026-09-30 |
$1.44 | $1.40 | $1.48 | -1.1% | -2.2% | 0↑ 2↓ | $8.9B | 3.9% | 2 |
| Current FY 2026-12-31 |
$4.84 | $4.74 | $4.97 | 2.8% | +0.1% | 1↑ 2↓ | $33.8B | 3.3% | 3 |
| Next FY 2027-12-31 |
$5.23 | $5.12 | $5.45 | 8.1% | +0.5% | 1↑ 2↓ | $35.4B | 4.9% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $1.248 | |
| 7d ago | $1.244 | +0.003 |
| 30d ago | $1.286 | -0.039 |
| 60d ago | $1.224 | +0.024 |
| 90d ago | $1.224 | +0.024 |
1 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jan 6, 2026 | Barclays | DOWNGRADE | Equal-Weight | Underweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 6 | 8 | 14 | 4 | 0 | 44% | |
| May 1, 2026 | 5 | 8 | 15 | 4 | 0 | 41% | |
| Apr 1, 2026 | 5 | 8 | 15 | 4 | 0 | 41% | |
| Mar 1, 2026 | 5 | 8 | 15 | 4 | 0 | 41% | |
| Feb 1, 2026 | 6 | 8 | 14 | 4 | 0 | 44% | |
| Jan 1, 2026 | 6 | 8 | 14 | 3 | 0 | 45% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
2 mentions
0 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Jun 9, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| Jun 9, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
SPRO - 50 Shades of Green
▲ 1
💬 1
⚡ 0.5
Jun 3, 2026
Clinical Trial
Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation
Phase Phase 2 — TERMINATED
Jun 3, 2026
Clinical Trial
A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis
Phase Phase 2 — TERMINATED
Jun 3, 2026
Clinical Trial
A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202
Phase Phase 2 — ACTIVE_NOT_RECRUITING
Jun 3, 2026
clinical_trial_readout
T-90d Trial Readout: Dostarlimab (Phase 2)
Trial: A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous
May 29, 2026
Clinical Trial
A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and Older
Phase Phase 2 — COMPLETED
May 28, 2026
clinical_trial_readout
Results Pending: Flu mRNA (Formulation A) (Phase 2) — Completed 17d ago
Trial: A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and Older
Sponsor: GlaxoSmithKline
Ph
May 28, 2026
Clinical Trial
A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy
Phase Phase 3 — COMPLETED
May 21, 2026
short_volume
Short Volume: GSK — 58.0% short (0.5M / 0.8M)
Short: 462,983 | Exempt: 528 | TRF Vol: 798,009 | Short Ratio: 58.0% | Off-exchange volume (dark pool + OTC)
May 20, 2026
short_volume
Short Volume: GSK — 59.6% short (0.5M / 0.8M)
Short: 476,154 | Exempt: 4,607 | TRF Vol: 799,427 | Short Ratio: 59.6% | Off-exchange volume (dark pool + OTC)
May 12, 2026
short_interest
FTD: GSK — 18,705 shares ($0.9M) failed to deliver
Settlement: 20260512, Price: $49.81, FTD Value: $931,696.05, GSK PLC SPONSORED ADR NEW (GBR
May 11, 2026
short_volume
Short Volume: GSK — 58.5% short (0.7M / 1.2M)
Short: 713,516 | Exempt: 1,146 | TRF Vol: 1,220,655 | Short Ratio: 58.5% | Off-exchange volume (dark pool + OTC)
May 8, 2026
short_volume
Short Volume: GSK — 55.4% short (0.4M / 0.7M)
Short: 409,089 | Exempt: 1,821 | TRF Vol: 737,944 | Short Ratio: 55.4% | Off-exchange volume (dark pool + OTC)
May 8, 2026
short_interest
FTD: GSK — 66,369 shares ($3.4M) failed to deliver
Settlement: 20260508, Price: $50.50, FTD Value: $3,351,634.5, GSK PLC SPONSORED ADR NEW (GBR
May 7, 2026
short_volume
Short Volume: GSK — 66.8% short (0.7M / 1.1M)
Short: 739,752 | Exempt: 333 | TRF Vol: 1,107,939 | Short Ratio: 66.8% | Off-exchange volume (dark pool + OTC)
May 6, 2026
short_volume
Short Volume: GSK — 62.7% short (0.8M / 1.3M)
Short: 784,005 | Exempt: 4,088 | TRF Vol: 1,251,339 | Short Ratio: 62.7% | Off-exchange volume (dark pool + OTC)
May 4, 2026
clinical_trial_readout
T-90d Trial Readout: Flu mRNA (Formulation B1) (Phase 2)
Trial: A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above
Sponsor: GlaxoSmithKline
Phase:
May 4, 2026
short_volume
Short Volume: GSK — 56.3% short (0.7M / 1.2M)
Short: 663,519 | Exempt: 268 | TRF Vol: 1,178,502 | Short Ratio: 56.3% | Off-exchange volume (dark pool + OTC)
May 2, 2026
clinical_trial_readout
T-90d Trial Readout: Flu mRNA (Formulation B1) (Phase 2)
Trial: A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above
Sponsor: GlaxoSmithKline
Phase:
May 1, 2026
short_volume
Short Volume: GSK — 62.2% short (1.0M / 1.6M)
Short: 1,000,417 | Exempt: 659 | TRF Vol: 1,608,444 | Short Ratio: 62.2% | Off-exchange volume (dark pool + OTC)
Apr 28, 2026
short_interest
FTD: GSK — 36,129 shares ($2.0M) failed to deliver
Settlement: 20260428, Price: $54.22, FTD Value: $1,958,914.38, GSK PLC SPONSORED ADR NEW (GBR
Mar 27, 2026
FDA
ZEJULA
Supplemental Approval — Labeling — NIRAPARIB — TABLET — ORAL
Mar 17, 2026
FDA
LYNAVOY
Original Approval — Type 1 - New Molecular Entity — TABLET
Mar 4, 2026
Enforcement
Roofers Local No. 149 Pension Fund, on behalf of itself and all others similarly situated v. GSK PLC, et al.
Court ruling from District Court, E.D. Pennsylvania. Docket: 2:25-cv-00618
Mar 2, 2026
FDA
Lamotrigine
WARNING: SERIOUS SKIN RASHES Lamotrigine can cause serious rashes requiring hospitalization and discontinuation of treatment. The incidence of these r
Apr 18, 2025
FDA
OJJAARA
Supplemental Approval — Labeling — MOMELOTINIB — TABLET — ORAL